Share
Isabel Kalofonos
Crinetics Pharmaceuticals, Inc. has appointed Isabel Kalofonos as Chief Commercial Officer, where she will lead the company’s commercial strategy and operations for the potential launch of paltusotine, a first-of-its-kind once-daily oral therapy for adults with acromegaly.
She will also drive pre-commercialization efforts for Crinetics’ innovative pipeline.
With over 20 years of global experience in pharma and biotech, Ms. Kalofonos has a track record of successful product launches across rare diseases, oncology, neurology, and immunology. Previously, she was SVP & CCO at ImmunoGen (acquired by AbbVie), where she led the launch of ELAHERE, a treatment for ovarian cancer. She also oversaw commercial strategy for the company’s antibody-drug conjugate pipeline.
Prior to that, Ms. Kalofonos was SVP & Global Head of the Prescription Business at Galderma, where she spearheaded launch preparations for NEMLUVIO (nemolizumab) for atopic dermatitis and prurigo nodularis, along with global market access, pricing, and real-world evidence strategies. She previously held senior roles at Takeda (formerly Shire), where she led the US$2.5 billion HAE franchise, including the blockbuster launch of TAKHZYRO (lanadelumab-flyo).
Ms. Kalofonos holds an MBA from Babson College and a degree in Industrial Engineering from Pontificia Universidad Javeriana.
As part of her appointment, Crinetics will grant her a stock option to purchase 100,000 shares under the company’s 2021 Inducement Plan, aligning her incentives with the company’s growth.
